Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Clin Cancer Res. 2014 Sep 1;20(17):4717-29. doi: 10.1158/1078-0432.CCR-13-3477. Epub 2014 Jun 30.
NAT10 (N-acetyltransferase 10) is a nucleolar protein, but may show subcellular redistribution in colorectal carcinoma. In this study, we evaluated membranous staining of NAT10 in colorectal carcinoma and its clinical implications, and explored the mechanism of regulation of NAT10 redistribution.
The expression and subcellular redistribution of NAT10, β-catenin, E-cadherin, and GSK-3β were evaluated by immunohistochemistry in 222 cases of colorectal carcinoma. Regulation of NAT10 and its influence on cell motility were analyzed with inhibitors of GSK-3β, transfection of wild-type or kinase-inactivated GSK-3β, or expression of various domains of NAT10, and evaluated with immunofluorescence, Western blotting, and Transwell assays.
NAT10 localized mainly in the nucleoli of normal tissues, and was redistributed to the membrane in cancer cells, particularly at the invasive "leading edge" of the tumor. This correlated well with nuclear accumulation of β-catenin (P<0.001; χ2=68.213). In addition, NAT10 membrane staining reflected the depth of invasion and tendency to metastasize (all P values<0.001), and was associated with a poorer prognosis (P=0.023; χ2=5.161). Evaluation of the mechanism involved demonstrated that subcellular redistribution of NAT10 may result from its increased stability and nuclear export, which is brought about by inhibition of GSK-3β. Moreover, redistribution of NAT10 induces alteration of cytoskeletal dynamics and increases cancer cell motility.
The subcellular redistribution of NAT10 can be induced by decreases in GSK-3β activity. This redistribution increases cancer cell motility, and is, thus, correlated with invasive potential and poorer clinical outcome. This finding suggests that NAT10 may be a useful prognostic marker and potential therapeutic target in colorectal carcinoma.
NAT10(N-乙酰基转移酶 10)是一种核仁蛋白,但在结直肠癌中可能显示亚细胞重新分布。在这项研究中,我们评估了 NAT10 在结直肠癌中的膜染色及其临床意义,并探讨了 NAT10 重新分布的调节机制。
通过免疫组织化学方法,在 222 例结直肠癌中评估 NAT10、β-连环蛋白、E-钙粘蛋白和 GSK-3β 的表达和亚细胞重新分布。使用 GSK-3β 抑制剂、野生型或激酶失活型 GSK-3β 的转染或 NAT10 的各种结构域的表达分析 NAT10 的调节及其对细胞迁移的影响,并通过免疫荧光、Western blot 和 Transwell 分析进行评估。
NAT10 在正常组织中主要定位于核仁,而在癌细胞中重新分布到膜上,特别是在肿瘤的侵袭“前沿”。这与核内β-连环蛋白的积累密切相关(P<0.001;χ2=68.213)。此外,NAT10 膜染色反映了侵袭深度和转移倾向(所有 P 值均<0.001),与预后较差相关(P=0.023;χ2=5.161)。对涉及的机制的评估表明,NAT10 的亚细胞重新分布可能是由于其稳定性和核输出的增加所致,这是由 GSK-3β 的抑制引起的。此外,NAT10 的重新分布诱导细胞骨架动力学的改变并增加癌细胞的迁移能力。
NAT10 的亚细胞重新分布可以通过 GSK-3β 活性的降低来诱导。这种重新分布增加了癌细胞的迁移能力,因此与侵袭潜能和较差的临床结局相关。这一发现表明,NAT10 可能是结直肠癌中一种有用的预后标志物和潜在的治疗靶点。